Baxter CEO steps down
Executive Summary
Baxter CEO Harry Kraemer plans to leave the company as soon as a successor is found. Baxter has been dogged by problems related to its plasma business and the adoption rate of the anti-hemophilic factor VIIIAdvate. Former Johnson & Johnson President James Lenehan is the most widely speculated candidate; other potential contenders are Integra LifeSciences CEO Stuart Essig and Garrett Capital Advisors Managing Partner Jim Connelly. Baxter has hired Heidrick & Struggles to head up the search...
You may also be interested in...
Baxter CEO is former Abbott exec
Former Abbott president Robert Parkinson, 53, becomes Baxter chairman and CEO on April 26. Parkinson's primary task will be to restore investor confidence and earnings visibility at Baxter after several quarters of missed earnings targets led to the resignation of Harry Kraemer as the company's top executive (1"The Pink Sheet" Feb. 2, 2004, In Brief). Parkinson has been dean of Loyola University Chicago's business school since 2002 and was Abbott Labs president and chief operating officer from 1999 to 2002...
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.